Simplifying Global Compliance
Inefficacy Kills Late-Stage Trial of Revlimid in Prostate Cancer
Clinical Trials Advisor
Celgene is stopping a Phase III trial of blockbuster myeloma drug Revlimid to treat castrate-resistant prostate cancer after the formulation failed to show benefit over placebo.
To View This Article:
Subscribe To Clinical Trials Advisor
Buy This Article Now
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing